Krystal Biotech (KRYS) Gross Margin (2023 - 2026)

Krystal Biotech (KRYS) has 4 years of Gross Margin data on file, last reported at 94.57% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin rose 27.0% year-over-year to 94.57%; the trailing twelve-month figure through Mar 2026 stood at 94.17% (up 97.0% YoY), and the FY2025 full-year result was 94.08%, up 98.0% from the prior year.
• Gross Margin improved to 94.57% in Q1 2026, from 93.85% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 97.39% in Q3 2023 to a low of 91.45% in Q2 2024.
• A 4-year average of 94.02% and a median of 94.3% in 2025 frame the typical range for Gross Margin.
• Across the five-year window, Gross Margin plunged 537 bps in 2024 and surged 361 bps in 2025, its largest moves.
• Tracing KRYS's Gross Margin over 4 years: stood at 93.19% in 2023, then grew by 1 bps to 94.57% in 2024, then retreated by 1 bps to 93.85% in 2025, then climbed by 1 bps to 94.57% in 2026.
• Business Quant data shows KRYS's Gross Margin at 94.57% in Q1 2026, 93.85% in Q4 2025, and 95.64% in Q3 2025.